Recently, ten listed companies for nucleic acid testing released the semi-annual report for 2022. At first glance, it is found that the total revenue of ten listed companies is 485 18 billion yuan, and the total net profit reaches/kloc-0.6297 billion yuan.
From the perspective of growth rate, the revenue and net profit of ten listed companies have achieved substantial growth. Jinyu Pharmaceutical has the smallest increase in net profit of 55. 1 1%, Mingde Bio has the fastest growth rate of 376.29%, and Wei Lan Pharmaceutical has exceeded 300%.
In terms of branches, Daan Gene is the most profitable, with revenue of 6.676 billion yuan, net profit of 43. 13 and profit rate of 64.6%.
In the semi-annual performance report of 2022, the company indicated that the market demand for nucleic acid detection kits, nucleic acid detection instruments and related consumables in novel coronavirus continued, which had a positive impact on the company's performance.
The revenue scale of Dean Diagnostics is the largest among the ten. In the first half of the year, the total revenue of the company's diagnostic service business was 6.952 billion yuan, an increase of 154. 10% compared with the same period of last year. Among them, COVID-19's income from nucleic acid testing was 4.748 billion yuan.